<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2008</study_start_year><condition>Metastatic colorectal adenocarcinoma with metastases involving the liver only</condition><condition>Colorectal cancer stage IV</condition><disease>Metastatic Colorectal Adenocarcinoma With Metastases Involving The Liver Only</disease><disease>Colorectal Cancer Stage Iv</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2518384</full_dataset_link><location>United Kingdom</location><study_start_month>5</study_start_month><keyword>Raltitrexed</keyword><keyword>Xeloda</keyword><keyword>Eloxatin</keyword><keyword>Avastin</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer</name><description>Primary objectives: To evaluate the response rate of patients with previously untreated unresectable liver-only metastases from colorectal cancer treated with neoadjuvant capecitabine and oxaliplatin plus bevacizumab.
Primary endpoints: Overall response rate according to RECIST criteria.</description><dates><creation>2008-05-15</creation></dates><accession>2518384</accession><cross_references><EU Clinical Trials Register>2005-004505-29</EU Clinical Trials Register></cross_references></HashMap>